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Background: Head and neck cancer is an important cause of ill health. Survival appears to be improving but the
reasons for this are unclear. They could include evolving aetiology, modifications in care, improvements in
treatment or changes in lifestyle behaviour. Observational studies are required to explore survival trends and
identify outcome predictors.
Methods: We are identifying people with a new diagnosis of head and neck cancer. We obtain consent that
includes agreement to collect longitudinal data, store samples and record linkage. Prior to treatment we give
participants three questionnaires on health and lifestyle, quality of life and sexual history. We collect blood and
saliva samples, complete a clinical data capture form and request a formalin fixed tissue sample. At four and twelve
months we complete further data capture forms and send participants further quality of life questionnaires.
Discussion: This large clinical cohort of people with head and neck cancer brings together clinical data,
patient-reported outcomes and biological samples in a single co-ordinated resource for translational and
prognostic research.
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Head and neck cancer, though less common in devel-
oped countries, is an important cause of mortality and
morbidity worldwide [1]. Survival is poor [2] and, des-
pite advances in treatment, has not improved until re-
cently [3]. The reasons for these recent improvements
are unclear. They could include changes in disease aeti-
ology or the fitness of people with disease, or alterna-
tively, an improvement in treatment or alterations in
lifestyle behaviour after treatment. The number of clin-
ical trials carried out in people with head and neck can-
cer has increased over recent years but there is a need* Correspondence: Andy.Ness@bristol.ac.uk
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proved survival and to identify predictors of outcome [4].
The importance of prognosis research has been high-
lighted recently [5,6]. Some questions in prognostic re-
search can be answered using routinely collected data or
existing studies designed for other purposes [6]. Clinical
cohorts, though expensive and time consuming, have a
number of advantages over other study designs. These in-
clude the recruitment of a potentially broad and represen-
tative sample with limited exclusion criteria; participants
with a shared (rather than staggered) clinical starting
point; the measurement of prognostic factors not used
in clinical practice; the inclusion of outcomes not rou-
tinely collected in existing sources (such as quality of
life) and the collection of biological samples that can be
analysed later. Many studies of disease prognosis have been
small and their protocols have not been clearly describedis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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designed, adequately-powered studies of this kind [5,6].
In this paper we describe the methods for a large UK-
based clinical cohort study in head and neck cancer
called Head and Neck 5000. The primary justification
for this study is to evaluate the impact of centralisation
of care for people with head and neck cancer; a future
publication will report on this evaluation. However, we
also intend to develop a well-phenotyped clinical cohort
that will provide a biomedical resource for translational
and prognostic research in head and neck cancer.Methods
Head and Neck 5000 is an observational study that re-
cruited people with head and neck cancer from across
the United Kingdom. We describe the: process of de-
signing and running the study; recruitment to the study;
baseline data collection; blood and saliva samples; tissue
samples; study follow-up; data management and statis-
tical power. The study protocol, questionnaires, consent
form and patient information leaflet were approved by
the National Research Ethics Committee (South West
Frenchay Ethics Committee, reference 10/H0107/57, 5th
November 2010) and subsequently approved by the re-
search and development departments for all partici-
pating NHS Trusts. We will make copies of the study
protocol and all documents described below available
on the study website when recruitment finishes (http://
www.headandneck5000.org.uk).Designing and running the study
We wanted to ensure that we drew on existing expertise
and experience and at the same time encouraged col-
laboration and a sense of ownership of the study among
clinicians treating people with head and neck cancer in
the UK. To achieve this we had a number of preliminary
discussions with key individuals and groups and hosted
several workshops to bring together clinicians, method-
ologists and patient representatives. At these workshops
we discussed and agreed both the principles and details
of the study. Our aim was, as far as possible, to map the
research protocol onto the treatment pathway of people
with head and neck cancer and so minimise impact on
both participants and clinicians. We also reduced the
burden on participants by limiting the size and fre-
quency of questionnaires, so as to encourage enrolment
and continued participation. Before starting recruitment
we completed a national survey of oncology centres and
multi-disciplinary teams treating head and neck cancer
that provided a picture of care nationally [7] We formally
initiated centres before they opened to data collection and
carry out visits to check on data quality. We have set
up a study website, send regular newsletters to centresand provide them with individual reports on their re-
cruitment and response rates.
Recruitment to the study
All people with a new diagnosis of head and neck cancer
are eligible to join the study. People with cancers in the
pharynx, mouth, larynx, salivary glands and thyroid are
all included. People with lymphoma, tumours of the skin
or a recurrence of a previous head and neck cancer are
excluded from the study. People have to be recruited be-
fore their treatment starts, unless their cancer treatment
was is their diagnostic procedure. Where this is the case
participants have to be recruited within a month of the
diagnostic procedure. Potential participants for whom the
decision is to provide palliative support are recruited as
soon after diagnosis as possible. Potentially eligible people
are identified by the multi-disciplinary team treating them.
A a member of the clinical team in the local centre intro-
duces the study to potential participants and either one of
the clinical team or the research nurse give them a copy
of the patient information leaflet. Participants are given
an opportunity to consider this leaflet. They are then
approached by a research nurse based in the local centre.
The nurse answers any questions they have and then ob-
tains written informed consent to participate in the study.
This consent is wide-ranging and includes agreement to:
collect, store and use biological samples; obtain samples of
stored tissue; carry out genetic analyses and collect infor-
mation from hospital notes and through record linkage.
The teams keep logs of the number of eligible people not
enrolled and the reason they were not recruited. The de-
tailed process of recruitment is adapted as necessary by
centres to ensure that it maps onto local practice in each
centre.
Baseline data collection
Having obtained informed consent the research nurse
gives the participant three questionnaires to take away,
complete and subsequently hand in to the clinic or return
to the study centre in a pre-paid envelope. The research
nurse offers to help complete any of the questionnaires
where necessary. A more detailed summary of the con-
tents of the questionnaires used at baseline and follow up
is included in Table 1. The first questionnaire is five pages
long and enquires about social and economic circum-
stances, overall health and lifestyle behaviours such as
smoking and alcohol consumption. The second question-
naire is nine pages long and enquires about physical and
psychological health, well-being and quality of life. The
version of this questionnaire used in the Bristol centre
contains an additional nine pages of questions on physical
appearance. The third questionnaire comprises just one
page and enquires about past sexual behaviours. The re-
search nurse explains that this is because of the role of
Table 1 Contents of questionnaires and data collection forms included in the head and neck 5000 clinical cohort study
Questionnaire Question set Research topic Number
of pages
Questionnaire pack
Data capture form Diagnosis and treatment Based on the UK National Head and neck
Cancer Audit [8]
1 Baseline, 4-month, 12-month
Co-morbidity Adult co-morbidity assessment 27 (ACE-27) [11] 1
Health and Lifestyle About You Demographic data, Education, occupation [12],
Income [13], EQ5D initially then EQ-5D-5 L [14],
Smoking [15,16], Alcohol [15,16]
4 Baseline, 4-month, 12-month
Quality of life Your Outlook Revised Life Orientation Test (LOT-R) [17] 1 Baseline, 4-month, 12-month
Your General Health EORTC QLQ-C30 [18] 2.5 Baseline, 4-month, 12-month
Specific Aspects of
Your Health
EORTC QLQ-H&N35 [19] 2 Baseline, 4-month, 12-month
Your Feelings Hospital Anxiety and Depression Scale (HADS) [20] 2 Baseline, 4-month, 12-month
Your Diet Three items (fruit, vegetables and deep fried food)
modified from the semi-quantitative Food,
Frequency Questionnaire [21]
1 Baseline, 4-month, 12-month
You and Cancer Fears of Recurrence [22] ½ 4-month, 12-month
Your Personal costs Designed by the study team 2 4-month , 12-month
Sexual history Sexual History Sexual History [23] 1 Baseline
Quality of life Your symptoms Head and neck radiotherapy questionnaire
(late toxicity) [24]
5 12-months (only people who
receive radiotherapy)
Withdrawal form Withdrawal from study Questions designed by the study team completed
by research nurse
1 As appropriate
Mortality form Place and mode of death Questions designed by the study team completed
by research nurse
2 As appropriate
Quality of life additional
questions used in Bristol
participants
Your Quality of Life The revised University of Washington (UW) QOL
questionnaire [25,26]
2 Baseline, 4-month, 12-month
Difficulties in Your Life The Social Difficulties Inventory (SDI) [27] 2 Baseline, 4-month, 12-month
Your Appearance The Derriford Appearance Scale (DAS 24) [28] 6 Baseline, 4-month, 12-month
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and neck cancer to ensure that people understand its rele-
vance and are not offended. Once the nurse has obtained
consent s/he abstracts information on diagnosis, treat-
ment and co-morbidity onto a short data capture form
using questions based on a national audit [8]. Centres are
encouraged to remind participants to complete question-
naires but this is not always possible (particularly where
the time between consent and starting treatment is short).
We code diagnosis using the International Classification
of Diseases (ICD) version 10 [9]. We derive the clinical
staging of the tumour from the T (characteristics of the
tumour site), N (degree of lymph node involvement) and
M (absence or presence of metastases) based on the
American Head and Neck Society TNM staging of head
and neck cancer [10].
Blood and saliva samples
Participants are asked to provide a blood sample and a
saliva sample. The research nurse collects 16 ml of ven-
ous blood and puts this in two EDTA tubes (10 ml and6 ml). For the saliva sample the local research nurse asks
the participant to rinse their mouth and once saliva is
flowing in their mouth to spit (at least 1 ml) into a ster-
ile screw top container. The research nurse then posts
the blood tubes and saliva container to the study centre
laboratory at ambient temperature in pre-paid approved
packaging, meeting UN Packaging Instruction PI650.
The blood samples are spun at 3500 rpm for 10 minutes.
The buffy coat layer is stored for future DNA extraction.
Up to 8 ml of plasma in total is stored in a selection of
200 μl and 500 μl plasma aliquots. Saliva samples are
divided into seven 1 ml samples. All samples are frozen
and stored at −80°C in the Avon Longitudinal Study of
Parents and Children (ALSPAC) bio-sample repository
(http://www.bristol.ac.uk/alspac/). DNA extraction is being
carried out by LGC genomics (http://www.lgcgenomics.
com/). To date 2,000 buffy coat samples have been
extracted using the Kleargene spin column extraction
method (http://www.lgcgroup.com/products/dna-extraction-
kits). Samples are eluted in 1 ml low salt buffer. DNA is
quantified using picogreen, the mean DNA concentration is
Ness et al. BMC Cancer 2014, 14:973 Page 4 of 6
http://www.biomedcentral.com/1471-2407/14/97397.21 ng/μl, (standard deviation 46 ng/μl), with a range of
<10 ng/μl (5 samples) to 404 ng/μl. 1795 samples have a
concentration >50 ng/μl.
Tissue samples
We obtain tissue either from the diagnostic procedure
or from the operation to remove the primary tumour.
We follow a hierarchy of access protocol so that local re-
search tissue banks have first access to tissue, with the
study only receiving additional tissue where available.
We ask the local pathologist to select one representative
paraffin embedded tumour block from the primary site
and if applicable, another from a matched lymph node
metastasis. The local pathology department also send an
anonymised copy of the participant’s histopathology re-
port with the tissue blocks and provide some brief de-
tails on the sample.
Study follow-up
We do not collect any further biological samples from
participants. We send out follow-up questionnaire packs
at four months and 12 months after the person joined
the study. These questionnaires repeat many of the ques-
tions included at baseline apart from those enquiring
about previous sexual behaviour. We have added ques-
tions on fear of recurrence at both four and 12 months
and questions on late radio-toxicity at 12 months. The
research nurses abstract updated information on diag-
nosis and treatment from the hospital medical record
onto a short data capture form at four and 12 months.
We flag study participants with the Health and Social
Care Information Centre (HSCIC) and we receive regu-
lar notifications of subsequent cancer registrations and
mortality among cohort members. Where someone has
died we ask research nurses in study centres to complete a
short questionnaire that enquires about the place and cir-
cumstances of death. When someone decides to withdraw
from the study we ask the research nurses in study centres
to complete a form giving the date, details and reason for
withdrawal.
Data management
The Bristol study team enters data from questionnaires
and the data capture form onto a central database with
automatic range and logic checks to reduce data entry
errors. We identify missing or inconsistent data on the
data capture forms, in particular where the initial diag-
nosis, stage or both are inaccurate or unclear. We check
data for these fields against text descriptions and path-
ology reports to minimise errors and missing data. We
contact study centres for further details where necessary.
We are carrying out double data entry on a 10% random
sample of questionnaires to establish the error rate andto identify key questionnaire sections that may require
double data entry for the whole cohort.Power calculation
Our power calculation was based on survival differences
across 4,000 participants. This allowed for exclusions of
rarer cancer types, withdrawals from the study, incom-
plete data and loss to follow-up from the target total of
5,000 enrolled. We initially assumed that people would
be recruited from 10 centres and allowed for clustering
by centre in the power calculation. If 2 year mortality
was 35% and two-sided alpha is 0.05 we calculated that
we would have 80% power to detect a difference in sur-
vival of around five percentage points for an intra-class
correlation coefficient (ICC) of 0.005 and of around
seven percentage points for an ICC of 0.01 (according to
an individual patient characteristic or a measure of the
quality of care they received split at the median). We
have updated our power calculation, based on our actual
recruitment from 78 centres, which indicates that we
will have 80% power to detect a difference in survival of
around four percentage points for an ICC of 0.005 and
of around five percentage points for an ICC of 0.01.Discussion
This large clinical cohort is successfully recruiting people
with head and neck cancer from across the UK. It is on
track to consent 5,000 people by the end of December
2014. The cohort recruits people before treatment starts
and obtains wide-ranging consent, clinical information,
self-reported socio-demographic, lifestyle and quality of
life data and biological samples.
We invested considerable time building a national cli-
nical consensus about the need for the study and in de-
signing the protocol before we started our fieldwork. We
opened to recruitment in a few centres initially to ensure
the protocol ran smoothly. This meant that there was
clinical support for the study and that the protocol was
ready to be rolled out, but this did delay our start date
and our initial rate of recruitment. The only specific
problem we have encountered was when one clinician
refused to allow people under his care to complete the
questionnaire on sexual behaviour. We were aware that
some people might find these questions sensitive so we
had put them in a separate questionnaire that was handed
out with a careful explanation from the research nurse.
We decided that all cancers treated by the head and
neck multi-disciplinary team should be included in the
study. We thought this would make the study easier to
recruit to, as everyone was eligible. Even though we ex-
pect that numbers for some tumours will be modest,
given the limited data on such tumours, we think that
this will still be potentially valuable.
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by NHS trusts. The hospital trusts are reimbursed in-
directly through the research networks. This means we
have no direct control over staffing levels or perform-
ance but on the other hand we do not have to appoint,
train or manage staff locally. As we have reported previ-
ously the process of recruiting to national clinical obser-
vational studies in the UK is not straightforward and is
often delayed by local processes [29]. Trusts are reim-
bursed for the number of people they recruit and not on
the response rate or the quality of the data they collect.
This study is a resource and we encourage future col-
laborations to ensure it is fully exploited. We are cur-
rently creating a detailed data dictionary and formalising
access arrangements. Details of these, copies of study
questionnaires and updates on recruitment will be made
available on our study website (http://www.headand-
neck5000.org.uk/). Around half of UK centres (and most
of the larger centres) treating people with head and neck
cancer are contributing to this study.
This study has therefore also created a national frame-
work with capacity to recruit people with head and neck
cancer into clinical research.
In conclusion we are creating a large DNA-backed
clinical cohort in people with head and neck cancer. As
with any large scale study it has limitations in terms of
recruitment rate and completeness of data. Nevertheless
we believe it will make important contributions to the
study of survival in people with head and neck cancer
and to prognosis research more generally. We welcome
collaboration and use of the resource.
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